Please provide your email address to receive an email when new articles are posted on . A transseptal mitral valve replacement system was approved for patients unsuitable for surgery or transcatheter ...

Piedmont Heart Institute (PHI) physicians Pradeep K. Yadav, M.D., Director of Structural Interventions, and Vinod H. Thourani, M.D., Marcus Chairman of Cardiovascular Surgery, successfully performed ...

Edwards Lifesciences has claimed an FDA approval for its Sapien M3 transcatheter mitral valve replacement system—marking the agency’s first in this type of implant that takes a potentially safer route ...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach ...

The US Food and Drug Administration has approved the Sapien M3 system for transseptal transcatheter mitral valve replacement (TMVR) for use in patients with symptomatic moderate-to-severe mitral ...

IRVINE, California - Edwards Lifesciences (NYSE:EW) has received U.S. Food and Drug Administration approval for its SAPIEN M3 mitral valve replacement system, marking the first transcatheter therapy ...

Edwards has received Food and Drug Administration approval for its Sapien M3 mitral valve replacement system, the company said Tuesday. The device is intended for people with moderate to severe mitral ...

The Sapien M3 heart valve is anchored in the heart with a catheter-delivered nitinol dock. [Image courtesy of Edwards Lifesciences] Edwards Lifesciences (NYSE: EW) + has won FDA approval for its ...

You will be redirected to our submission process. The advent of transcatheter mitral valve repair (TMVr) and replacement (TMVR) has marked a revolutionary shift in the management of mitral valve ...